<DOC>
	<DOCNO>NCT01009476</DOCNO>
	<brief_summary>The main objective non-interventional study document long-term application galantamine nootropics ( memory enhance drug ) period 1 year condition daily routine . There predefined specification diagnostic therapeutic measure . The decision treatment either galantamine nootropic make treat physician prior start documentation . The following measure document : safety , tolerability , dementia-associated symptom ( unstable walking , vertigo , awaken night , shouting/screaming night , perambulate night , aggressiveness , agitation , apathy/social retreat , delusion , hallucination , behavior pose risk self others , daytime tiredness ) , frequency admission nurse home nurse service , global functional level , caregiver 's burden , time spent caregiving . Furthermore , study aim gather knowledge differentiate use two treatment strategy consider specific diagnosis dementia ( e.g . Alzheimer 's disease mixed dementia , i.e . Alzheimer 's disease cerebrovascular disease ) risk profile .</brief_summary>
	<brief_title>Long-term Use Galantamine Versus Nootropics ( Memory Enhancing Drugs ) Patients With Alzheimer 's Dementia Under Conditions Daily Routine</brief_title>
	<detailed_description>The aim observational , non-interventional study observe document 1-year period , long-term use galantamine nootropics ( memory enhance drug ) 1 year period condition daily routine typical patient population patient mild moderate Alzheimer 's dementia mixed dementia , i.e . Alzheimer 's cerebrovascular disease . The design prospective study non-interventional thus , predefined specification diagnostic therapeutic measure . The decision treatment either galantamine nootropic agent make treat physician prior start documentation . Patients observe period 12 month end documentation ( visit 1 = baseline ; visit 2 , 3 4 approximately 2 , 6 9 month , respectively ; visit 5 approximately 12 month final visit end documentation ) . The following measure document : safety document adverse serious adverse event together severity , outcome causality treatment ; tolerability ; vital function ; Global Deterioration Scale ( GDS ) stag system assess global functioning ; Mini-Mental State Examination assess cognitive function ; dementia-associated behavioural symptom ( unstable walking , vertigo , awaken night , shouting/screaming night , perambulate night , aggressiveness , agitation , apathy/social retreat , delusion , hallucination , behavior pose risk self others , daytime tiredness ) ; frequency admission nurse home nurse service ; caregiver 's burden time spend caregiving ( base daily weekly caregiving task ) ; final evaluation therapy galantamine nootropics treat physician . Furthermore , study aim gather knowledge differentiate use two treatment strategy consider specific diagnosis dementia ( e.g . Alzheimer 's disease mixed dementia , i.e . Alzheimer 's disease cerebrovascular disease ) risk profile . Therapeutic measure predefined protocol remain discretion treat physician . Therapy decision base medical need . The treatment regimen galantamine ( 8 mg,16 mg , 24 mg retard capsule ) nootropic agent ( e.g . ginkgo biloba , dihydroergotoxine , nicergoline , piracetam , others ) accordance recommendation give summary product characteristic ( SmPC ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Nicergoline</mesh_term>
	<mesh_term>Nootropic Agents</mesh_term>
	<criteria>Patients select documentation decision treatment ( galantamine nootropic ) make treat physician . Patients document study require meet follow selection criterion : Diagnosis probable mild moderate dementia : Alzheimer type mixed dementia ( Alzheimer 's cerebrovascular disease ) MiniMentalState Examination score = 24 baseline ( Visit 1 ) , possible Monotherapy either galantamine nootropic ( decision treatment either galantamine nootropic make treat physician prior start documentation ) Patient caregiver personal contact possible least 3 time per week Patients eligible received antidementive treatment acetylcholinesterase inhibitor , memantine , nootropic use observational period within last 12 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Cholinesterase inhibitor</keyword>
	<keyword>Nootropic agent</keyword>
	<keyword>Alzheimer</keyword>
	<keyword>Vascular dementia</keyword>
	<keyword>Cognitive symptom</keyword>
	<keyword>Behavioural symptom</keyword>
	<keyword>Care give time</keyword>
</DOC>